|کد مقاله||کد نشریه||سال انتشار||مقاله انگلیسی||ترجمه فارسی||نسخه تمام متن|
|2659748||1140308||2016||4 صفحه PDF||سفارش دهید||دانلود کنید|
• Entyvio is effective for patients with ulcerative colitis and Crohn's disease.
• We discuss the nurse practitioner’s role in the protocol development for Entyvio administration.
• Entyvio is contraindicated in patients with active tuberculosis disease and screening needed.
Vedolizumab (Entyvio, Takeda Pharmaceuticals America, Inc., Deerfield, IL) is one of several treatment options for the management of ulcerative colitis and Crohn's disease. It is a recombinant humanized anti–alpha-4-beta-7 integrin monoclonal antibody. This biologic immunotherapy is used in patients who have failed or achieved inadequate response to the different therapies currently available for these disease processes. Certain considerations include monitoring for tuberculosis, and the administration of immunizations before the initiation of therapy. A protocol for the safe administration of vedolizumab at New York University Center for Musculoskeletal Care Infusion Center is based on current prescribing guidelines.
Journal: The Journal for Nurse Practitioners - Volume 12, Issue 3, March 2016, Pages e101–e104